Financial Analysis: PAVmed (NASDAQ:PAVM) versus Motus GI (NASDAQ:MOTS)

PAVmed (NASDAQ:PAVM) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares PAVmed and Motus GI’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PAVmed N/A -9,072.85% -119.06%
Motus GI N/A -155.61% -117.80%

Analyst Ratings

This is a summary of current recommendations for PAVmed and Motus GI, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAVmed 0 0 1 0 3.00
Motus GI 0 0 4 0 3.00

PAVmed currently has a consensus target price of $3.00, indicating a potential upside of 188.46%. Motus GI has a consensus target price of $9.63, indicating a potential upside of 216.61%. Given Motus GI’s higher possible upside, analysts plainly believe Motus GI is more favorable than PAVmed.

Institutional & Insider Ownership

1.8% of PAVmed shares are owned by institutional investors. Comparatively, 35.3% of Motus GI shares are owned by institutional investors. 34.4% of PAVmed shares are owned by company insiders. Comparatively, 18.1% of Motus GI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares PAVmed and Motus GI’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PAVmed N/A N/A -$17.97 million N/A N/A
Motus GI $40,000.00 1,630.20 -$22.26 million ($1.23) -2.47

PAVmed has higher earnings, but lower revenue than Motus GI.

Volatility and Risk

PAVmed has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Summary

Motus GI beats PAVmed on 7 of the 9 factors compared between the two stocks.

PAVmed Company Profile

PAVmed Inc. operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

Motus GI Company Profile

Motus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company is based in Fort Lauderdale, Florida.

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.